Dr. Irina Belinsky, MD

Dr. Belinsky practices at Texas Oculoplastic Consultants PLLC in Austin, Texas.

Dr. Belinsky's NPI, 1073831087, was assigned on May 14, 2010. Dr. Belinsky graduated from Sidney Kimmel Medical College in 2010. Dr. Belinsky holds Texas license U1472.

Dr. Belinsky's primary practice is Texas Oculoplastic Consultants PLLC, at 3705 Medical Pkwy, Austin, TX 78705 in Travis County. The practice phone is (512) 458-2141.

Dr. Belinsky's primary practice is Texas Oculoplastic Consultants PLLC in Austin, Texas. Dr. Belinsky is also affiliated with Ascension Seton Medical Center Austin. Dmand AI also links Dr. Belinsky to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Belinsky practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Belinsky's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Belinsky is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Belinsky's licenses on file in 3 states: Texas, New York and Pennsylvania.

Dmand AI lists dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Belinsky treats.

CMS data shows 557 Medicare services from Dr. Belinsky across 12 procedure codes in 2024, for 263 Medicare patients. Medicare paid $86,487 for them.

CMS counts 263 Medicare patients who saw Dr. Belinsky in 2024. The largest group is 65 to 74, with 121 patients. 75% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Belinsky's median patient age at 67, with 65% women.

In 2024, Dr. Belinsky wrote 448 Medicare Part D claims for 258 patients. 92% of them were for generic drugs. CMS names the drug for 414 of them, across 4 drugs with 11 or more claims each, at $5,730 in total drug cost. In 2023, CMS named 273 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 71 out of 100 for Dr. Belinsky for performance year 2024, reported individually. Dr. Belinsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 52 papers to Dr. Belinsky, published from 2010 to 2024. 2020 was the busiest year, with 7. The most frequent topics are Biopsy, Conjunctiva and Conjunctival Neoplasms. Dr. Belinsky has published most often in Ophthalmic Plast Reconstr Surg. Dr. Belinsky's most frequent co-authors are Norman C. Charles, MD, Andrea Tooley and Brian P. Marr, MD.

CMS Open Payments shows 44 general payments to Dr. Belinsky from 13 drug and device companies from 2018 to 2025. Honoraria make up the largest share, 64% of the total. Horizon Pharma plc paid the most, $3,374.

Dr. Belinsky graduated from Sidney Kimmel Medical College in 2010.

Dr. Belinsky is in network with 22 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.